A Phase 2 interventional study of cariprazine and cariprazine in Bipolar Depression, sponsored by Forest Laboratories. Completed at 26 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-23.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.
Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 6 in phase 2, and was the 3rd registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.
Browse Bipolar Disorder studies →2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 64 across 1,279 interventional studies indexed under Bipolar Disorder.
Median enrollment 234 across the 11 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
2 of the studies in Bipolar Disorder by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07071532AbbVieA Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder | 2027-02 |
| NCT06696755AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Bipolar Disorder by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of cariprazine in the treatment of outpatients with bipolar depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing.
Drug: cariprazine
1.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing.
Drug: cariprazine
Matching placebo capsules, oral administration, once daily dosing.
Drug: placebo
Drug: cariprazine (0.25 - 0.75 mg/day)
Drug: cariprazine (1.5 - 3.0 mg/day)
placebo capsules, oral administration, once daily dosing
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
The patient is rated on a scale from 0-6 on 10 items. Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel. The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity.
Time frame: Baseline to Week 8
Change in Baseline in Clinical Global Impressions-Improvement ( CGI-I )
The patient was rated on a scale from 1 to 7, with 1 indicating the patient was very much improved and 7 indicating that the patient was very much worse.
Time frame: Baseline to Week 8
| Milestone | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0 mg Cariprazine |
|---|---|---|---|
| Started | 77 | 75 | 75 |
| Completed | 60 | 63 | 49 |
| Not completed | 17 | 12 | 26 |
| Withdrew: Adverse event | 2 | 3 | 7 |
| Withdrew: Lack of efficacy | 4 | 1 | 2 |
| Withdrew: Protocol violation | 2 | 2 | 7 |
| Withdrew: Withdrawal by subject | 3 | 1 | 2 |
| Withdrew: Lost to follow-up | 5 | 5 | 6 |
| Withdrew: Pregnancy,moving away and surgery | 1 | 0 | 2 |
The patient is rated on a scale from 0-6 on 10 items. Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel. The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity.
| Score on scale | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0 mg Cariprazine |
|---|---|---|---|
| Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) | 29.9 ± 0.6 | 30.2 ± 0.6 | 30.9 ± 0.6 |
The patient was rated on a scale from 1 to 7, with 1 indicating the patient was very much improved and 7 indicating that the patient was very much worse.
| Score on Scale | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0mg Cariprazine |
|---|---|---|---|
| Change in Baseline in Clinical Global Impressions-Improvement ( CGI-I ) | 2.1 ± 0.1 | 2.1 ± 0.1 | 2.1 ± 0.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/77 (2.6%) | 51/77 (66.2%) |
| 0.25 to 0.75 mg Cariprazine | — | 2/75 (2.7%) | 48/75 (64%) |
| 1.5 to 3.0 mg Cariprazine | — | 2/75 (2.7%) | 52/75 (69.3%) |
| Event | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0 mg Cariprazine |
|---|---|---|---|
| Bipolar I disorderPsychiatric disorders | 0/77 | 0/75 | 1/75 |
| Suicidal ideationPsychiatric disorders | 1/77 | 0/75 | 1/75 |
| Suicidal attemptPsychiatric disorders | 0/77 | 1/75 | 0/75 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/77 | 1/75 | 0/75 |
| DepressionPsychiatric disorders | 0/77 | 0/75 | 1/75 |
| Bipolar disorderPsychiatric disorders | 1/77 | 0/75 | 0/75 |
| Event | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0 mg Cariprazine |
|---|---|---|---|
| InsomniaPsychiatric disorders | 7/77 | 13/75 | 15/75 |
| AkathisiaNervous system disorders | 5/77 | 2/75 | 13/75 |
| HeadacheNervous system disorders | 12/77 | 11/75 | 12/75 |
| Upper respiratory tract infectionInfections and infestations | 8/77 | 11/75 | 8/75 |
| DiarrhoeaGastrointestinal disorders | 5/77 | 10/75 | 5/75 |
| Dry mouthGastrointestinal disorders | 4/77 | 7/75 | 10/75 |
| NauseaGastrointestinal disorders | 4/77 | 9/75 | 9/75 |
| NasopharyngitisInfections and infestations | 5/77 | 7/75 | 7/75 |
| FatigueGeneral disorders | 5/77 | 7/75 | 6/75 |
| Weight IncreaseInvestigations | 1/77 | 1/75 | 6/75 |
| Age, Continuous(Years) | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0 mg Cariprazine | Total |
|---|---|---|---|---|
| Mean | 40.6 ± 10.7 | 37.4 ± 10.7 | 38.8 ± 12.1 | 38.9 ± 11.2 |
| Age, Customized(Participants) | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0 mg Cariprazine | Total |
|---|---|---|---|---|
| < 20 | 1 | 1 | 2 | 4 |
| 20, 30 | 11 | 21 | 18 | 50 |
| 30, 40 | 24 | 20 | 20 | 64 |
| 40, 50 | 23 | 23 | 20 | 66 |
| 50, 60 | 17 | 10 | 13 | 40 |
| ≥ 60 | 1 | 0 | 2 | 3 |
| Sex/Gender, Customized(participant) | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0 mg Cariprazine | Total |
|---|---|---|---|---|
| Female | 46 | 48 | 51 | 145 |
| Male | 31 | 27 | 24 | 82 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0 mg Cariprazine | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 6 | 13 |
| Not Hispanic or Latino | 74 | 71 | 69 | 214 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | 0.25 to 0.75 mg Cariprazine | 1.5 to 3.0 mg Cariprazine | Total |
|---|---|---|---|---|
| Caucasian | 54 | 56 | 62 | 172 |
| Non-Caucasian | 23 | 19 | 13 | 55 |
| Black | 19 | 16 | 11 | 46 |
| Asian | 2 | 2 | 1 | 5 |
| Other | 2 | 1 | 1 | 4 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
Ran from Jun 2009 to primary completion in Jun 2010, 11 months.
Results were first posted in Aug 2018, 8 years 2 months after primary completion. A results delay was requested in Jul 2011.
Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 60. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine